Tamara van Donge

Key components for antibiotic dose optimization 55 3 20. Quiros Y, Vicente-Vicente L, Morales AI, López-Novoa JM, López-Hernández FJ. An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin. Toxicological Sciences. 2010;119(2):245-256. 21. Lopez SA, Mulla H, Durward A, Tibby SM. Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness. Pediatric Critical Care Medicine. 2010;11(2):267-274. 22. Allegaert K, Velde M, Anker J. Neonatal clinical pharmacology. Pediatric Anesthesia. 2014;24(1):30- 38. 23. van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. In: Pediatric Clinical Pharmacology. Springer; 2011:51-75. 24. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. New England Journal of Medicine. 2003;349(12):1157-1167. 25. Wilbaux M, Fuchs A, Samardzic J, et al. Pharmacometric approaches to personalize use of primarily renally eliminated antibiotics in preterm and term neonates. The Journal of Clinical Pharmacology. 2016;56(8):909-935. 26. Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children. Clinical Pharmacokinetics. 2015;54:1183-1204. 27. Marchand S, Chauzy A, Dahyot-Fizelier C, Couet W. Microdialysis as a way to measure antibiotics concentration in tissues. Pharmacological research. 2016;111:201-207. 28. Darwich A, Ogungbenro K, Vinks A, et al. Why has model‐informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clinical Pharmacology & Therapeutics. 2017;101(5):646-656. 29. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/ pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. Journal of antimicrobial Chemotherapy. 2005;55(5):601-607. 30. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/ pharmacodynamic (PK/PD) terminology for anti-infective drugs. International journal of antimicrobial agents. 2002;19(4):355-358. 31. Schmidt S, Barbour A, Sahre M, Rand KH, Derendorf H. PK/PD: new insights for antibacterial and antiviral applications. Current opinion in pharmacology. 2008;8(5):549-556. 32. Sherwin K, Zhuang L, Derendorf H. Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. Expert opinion on drug metabolism & toxicology. 2016;12(1):93-114. 33. Eagle H, Fleischman R, Levy M. Continuous vs. discontinuous therapy with penicillin: the effect of the interval between injections on therapeutic efficacy. New England journal of medicine. 1953;248(12):481-488. 34. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once‐daily aminoglycoside dosing. British journal of clinical pharmacology. 1995;39(6):605-609. 35. Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA. Applying pharmacokinetic/ pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Seminars in respiratory and critical care medicine. 2015;36(1):136-153. 36. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases. 1987;155(1):93-99. 37. Spivey J. The postantibiotic effect. Clinical pharmacy. 1992;11(10):865-875. 38. Ehrlich P. Address in Pathology, ON CHEMIOTHERAPY: Delivered before the Seventeenth International Congress of Medicine. British Medical Journal. 1913;2(2746):353-359.